CLL Treatment Advances:
Moving From Research to Reality
Targeted Therapies, Breakthrough Combinations, and MRD
The world of CLL treatment is evolving fast, with new breakthroughs offering more options and greater precision than ever before.
This program brings together expert Dr. Jeff Sharman and patient advocate Andrew Schorr to break down the most important updates from recent research and clinical trials. Learn what’s changing, how it impacts treatment decisions, and what it all means for patients today.
📅 Airs: Monday, March 31 at 3 PM PT | 6 PM ET
Program Topics:
- New Treatment Advances: Get the latest updates on targeted therapies, combination approaches, and next-generation treatments.
- Understanding MRD: Learn how minimal residual disease (MRD) testing is shaping treatment strategies.
- Clinical Trials & Personalized Care: Discover how biomarkers and ongoing research are changing the CLL treatment landscape.
- Expert Insights & Patient Focus: Hear from Dr. Jeff Sharman and Andrew Schorr on what this means for patients now and in the future.
Program Speakers
Jeff
Sharman, MD
Hematology-Oncology
Director of Research - Willamette Valley Cancer Institute Medical Director of Hematology Research - The US Oncology Network
Andrew
Schorr
Program Host
Chronic Lymphocytic Leukemia
Patient Advocate
Thank you to AbbVie Company, for its support of our patient education program. The Patient Story retains full editorial control over all content.